Frag 176-191 Dosage and Cycle

Sep 10, 2024 Leave a message

The limited efficacy of orally-administered human growth hormone fragment 176-191 (frag 176-191) has informed our position that frag 176-191 would be best administered via subcutaneous injection, similar to hGH.

Since frag 176-191 peptide's discontinuation for clinical evaluation, expert opinion has shifted such that an appropriate dosing range for subcutaneously injected frag 176-191 would be approximately 200-500mcg per day, for purposes of inducing weight loss in subjects.

Although frag 176-191's equivalent AOD9604 was demonstrated to have an excellent safety profile, tolerance of subcutaneous injections should still be initially assessed using conservative doses.

 

A hypothetical Frag 176-191 dosing protocol to help researchers understand potential study design is as follows:

Initial dose: To assess tolerance, begin with a frag 176-191 dose of 100mcg injected subcutaneously. Note that 1mg is equal to 1000mcg, and 100mcg is equal to 1/10th of a milligram.

Subsequent doses: If the initial dose is well tolerated, escalate dosing to between 200-500mcg per injection, depending on the goals of the study.

Administration timing and frequency: Based on what is understood about hGH pharmacokinetics and pharmacodynamics, frag 176-191 is likely best administered on an empty stomach, approximately 30 minutes to 1 hour prior to exercise. Note that the total daily dosage can be split between a morning and evening injection.

For intranasal formulations of frag 176-191, bioavailability will be lower due to reduced absorption of the peptide solution through the nasal membrane, compared with injection. To compensate for reduced systemic absorption, researchers could consider using the same protocol listed above, but with doses increased at each step by up to 50%.

 

product-672-393

 

Send Inquiry

whatsapp

Phone

E-mail

Inquiry